Free Trial

Dianthus Therapeutics (DNTH) News Today

Dianthus Therapeutics logo
$19.99 -1.56 (-7.24%)
Closing price 03:59 PM Eastern
Extended Trading
$19.97 -0.02 (-0.10%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Avidity Partners Management LP
Avidity Partners Management LP lessened its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 1.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,873,000 shares of the company's stock after s
Dianthus Therapeutics, Inc. stock logo
Allostery Investments LP Takes Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)
Allostery Investments LP bought a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 25,000 shares of the company's stock, valued at approximately
Dianthus Therapeutics, Inc. stock logo
Ally Bridge Group NY LLC Buys New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)
Ally Bridge Group NY LLC purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 106,434 shares of the company's sto
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is 5AM Venture Management LLC's 6th Largest Position
5AM Venture Management LLC reduced its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 16.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,027,711 shares of the company's stoc
Dianthus Therapeutics, Inc. stock logo
RA Capital Management L.P. Sells 466,600 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)
RA Capital Management L.P. lowered its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 20.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,866,400 shares of the company's stock after sel
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on Thursday
Dianthus Therapeutics (NASDAQ:DNTH) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-dianthus-therapeutics-inc-stock/)
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have been assigned a consensus rating of "Buy" from the nine analysts that are covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to t
Dianthus Therapeutics, Inc. stock logo
Adage Capital Partners GP L.L.C. Buys Shares of 180,000 Dianthus Therapeutics, Inc. (NASDAQ:DNTH)
Adage Capital Partners GP L.L.C. purchased a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 180,000 shar
Dianthus Therapeutics, Inc. stock logo
TCG Crossover Management LLC Acquires Shares of 1,501,624 Dianthus Therapeutics, Inc. (NASDAQ:DNTH)
TCG Crossover Management LLC bought a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,501,624 shares of the company's stock, valu
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - Here's What Happened
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - Here's Why
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.4% - Here's Why
Dianthus Therapeutics (NASDAQ:DNTH) Trading 7.4% Higher - What's Next?
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Bain Capital Life Sciences Investors LLC
Bain Capital Life Sciences Investors LLC lowered its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 10.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,689,707 shares of the company's stock afte
Dianthus Therapeutics, Inc. stock logo
Walleye Capital LLC Buys 52,890 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)
Walleye Capital LLC lifted its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 176.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 82,890 shares of the company's stock after acquiring an additional 52,890 shar
Dianthus Therapeutics, Inc. stock logo
Fmr LLC Buys 36,133 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)
Fmr LLC lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 0.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,439,281 shares of the company's stock after purchasing an additional 36
Dianthus Therapeutics, Inc. stock logo
Vanguard Group Inc. Sells 20,331 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)
Vanguard Group Inc. lessened its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 1.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,274,638 shares of the company's stock after selling 20,331 shares during the qu
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by ADAR1 Capital Management LLC
ADAR1 Capital Management LLC decreased its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 85.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 17,683 shares of the company's stock after se
Dianthus Therapeutics, Inc. stock logo
Alliancebernstein L.P. Has $25.28 Million Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)
Alliancebernstein L.P. boosted its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 13.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,159,776 shares of the company's stock after acquiring an
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Rhenman & Partners Asset Management AB
Rhenman & Partners Asset Management AB lowered its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 24.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 114,000 shares of the co
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Buy" from Brokerages
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has received an average recommendation of "Buy" from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and two have issued a
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase - Still a Buy?
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume - Should You Buy?
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week Low - Should You Sell?
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 1-Year Low - Here's What Happened
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 7% - Here's What Happened
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 7% - Here's Why
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 6.5% - Should You Buy?
Dianthus Therapeutics (NASDAQ:DNTH) Trading 6.5% Higher - Here's Why
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 52-Week Low - What's Next?
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year Low - Here's What Happened
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.8% - Here's Why
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8% - Here's What Happened
Dianthus Therapeutics, Inc. stock logo
FY2025 EPS Estimates for DNTH Raised by Cantor Fitzgerald
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for Dianthus Therapeutics in a research note issued to investors on Thursday, March 13th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the c
Dianthus Therapeutics, Inc. stock logo
HC Wainwright Issues Optimistic Outlook for DNTH Earnings
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Investment analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for Dianthus Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst S. Ramakanth now forec
Dianthus Therapeutics, Inc. stock logo
What is Lifesci Capital's Estimate for DNTH FY2025 Earnings?
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at Lifesci Capital increased their FY2025 earnings estimates for shares of Dianthus Therapeutics in a research note issued to investors on Wednesday, March 12th. Lifesci Capital analyst R. Katkhuda now expects that the co
Dianthus Therapeutics, Inc. stock logo
Wedbush Analysts Decrease Earnings Estimates for DNTH
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at Wedbush decreased their Q1 2025 EPS estimates for shares of Dianthus Therapeutics in a research note issued on Wednesday, March 12th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.74) per shar
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - Here's Why
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - What's Next?
Dianthus Therapeutics, Inc. stock logo
Wedbush Reaffirms Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH)
Wedbush reiterated an "outperform" rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday.
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics' (DNTH) "Buy" Rating Reaffirmed at Guggenheim
Guggenheim reaffirmed a "buy" rating and set a $84.00 target price on shares of Dianthus Therapeutics in a report on Wednesday.
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics' (DNTH) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday.
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Thursday
Dianthus Therapeutics (NASDAQ:DNTH) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (NASDAQ:DNTH) Announces Earnings Results, Beats Estimates By $0.04 EPS
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% - Time to Sell?
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% - What's Next?
Dianthus reports Q4 EPS (81c), consensus (76c)
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by Brokerages
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine analysts that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and two have issued a st
Dianthus Therapeutics, Inc. stock logo
Dianthus Therapeutics (NASDAQ:DNTH) Trading 8.2% Higher - Here's Why
Dianthus Therapeutics (NASDAQ:DNTH) Trading 8.2% Higher - What's Next?
Get Dianthus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter.

DNTH Media Mentions By Week

DNTH Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

DNTH
News Sentiment

1.08

0.69

Average
Medical
News Sentiment

DNTH News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

DNTH Articles
This Week

13

3

DNTH Articles
Average Week

Get Dianthus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:DNTH) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners